Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | CHIEF FINANCIAL OFFICER | March 27, 2023 | March 29, 2023 |
| Replimune Group, Inc.REPL · Entity 4707 | Chief Financial Officer | August 17, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date March 27, 2023 · Filed March 29, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,925 |
Reported balance
After 2023-03-27 transaction · row 1
1 source rowRow 1 · 2023-03-27 · Sale · Disposed 7,363 · Balance 38,925 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023.
Replimune Group, Inc.
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 215,852 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Sale · Disposed 9,256 · Balance 215,852 F1: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. F2: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $14.20 to $14.28 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.
F2: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $14.20 to $14.28 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 19, 2026 22:42 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 9,256 | $14.28 | $132,175.68 |
DisclosureSEC source: 0001104659-26-098868 · tm2623510-1_4seq1.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,852 F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $14.20 to $14.28 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 21:06 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 11,448 | $12.97 | $148,480.56 |
DisclosureSEC source: 0001104659-26-095008 · tm2623037-3_4seq1.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,108 F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the vesting of the Reporting Person's performance-based restricted stock units (the "PSUs"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the PSUs were granted and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:15 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 7,812 | $5.08 | $39,684.96 |
DisclosureSEC source: 0001104659-26-064517 · tm2615137-1_4seq1.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,556 F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $5.01 to $5.08 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range. Read SEC document |
| April 01, 2026 Filed Apr 8, 2026 01:08 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $7.61 | $0.00 |
DisclosureSEC source: 0001104659-26-040566 · tm2611350-2_4seq1.xml · derivative · entry 2 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2027, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2026 Filed Apr 8, 2026 01:08 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-040566 · tm2611350-2_4seq1.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,368 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2027 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2030, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| December 19, 2025 Filed Dec 19, 2025 22:12 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-123285 · tm2533977-3_4seq1.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,368 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 50% of the RSUs will vest on November 15, 2026 and 50% of the RSUs will vest on November 15, 2027, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| August 15, 2025 Filed Aug 20, 2025 00:30 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 9,154 | $5.37 | $49,156.98 |
DisclosureSEC source: 0001104659-25-080403 · tm2523886-1_4seq1.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,368 F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| May 20, 2025 Filed May 23, 2025 01:44 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 2,535 | $8.05 | $20,406.75 |
DisclosureSEC source: 0001104659-25-052142 · tm2515608-3_4seq1.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,522 F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $8.05 to $8.79 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range. Read SEC document |
| April 01, 2025 Filed Apr 4, 2025 00:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 67,500 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0001104659-25-031829 · tm2511407-5_4seq1.xml · derivative · entry 2 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2035-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2026, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2025 Filed Apr 4, 2025 00:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-031829 · tm2511407-5_4seq1.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,057 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2026 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2029, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 00:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 8,938 | $10.18 | $90,988.84 |
DisclosureSEC source: 0001104659-24-090980 · tm2422092-1_4seq1.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,057 F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $10.18 to $10.20 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001104659-24-043253 · tm2410652-5_4seq1.xml · derivative · entry 2 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2034-04-01 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2025, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:01 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 26,665 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-043253 · tm2410652-5_4seq1.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,995 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2025 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2028, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| September 18, 2023 Filed Sep 21, 2023 00:04 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001104659-23-102485 · tm2326425-2_4seq1.xml · derivative · entry 2 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-09-18 F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on September 18, 2024, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| September 18, 2023 Filed Sep 21, 2023 00:04 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantCommon Stock | 83,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-102485 · tm2326425-2_4seq1.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,330 F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on August 15, 2024 and the remainder will vest in three approximately equal annual installments thereafter until August 15, 2027, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:19 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 7,363 | $45.00 | $331,335.00 |
DisclosureSEC source: 0001415889-23-005564 · form4-03292023_080359.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,925 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 575 | $45.63 | $26,236.10 |
DisclosureSEC source: 0001415889-23-001798 · form4-02022023_090208.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,288 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,325 RSUs from a January 29, 2020 grant of 9,300 RSUs. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 21:21 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 223 | $47.45 | $10,581.64 |
DisclosureSEC source: 0001415889-23-001459 · form4-01262023_090124.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,863 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 909 RSUs from a January 22, 2019 grant of 3,636 RSUs. Read SEC document |
| January 11, 2023 Filed Jan 12, 2023 21:37 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 418 | $44.36 | $18,542.31 |
DisclosureSEC source: 0001415889-23-000880 · form4-01122023_090143.xml · nonDerivative · entry 2 Hill Emily Luisa · CIK 0001778279 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,086 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 3,900 RSUs from a January 7, 2022 grant of 15,600 RSUs. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 21:37 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 497 | $42.93 | $21,337.65 |
DisclosureSEC source: 0001415889-23-000880 · form4-01122023_090143.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,504 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 3,900 RSUs from a January 7, 2022 grant of 15,600 RSUs. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 23:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 758 | $41.66 | $31,575.40 |
DisclosureSEC source: 0001415889-23-000838 · form4-01112023_110136.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,001 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,700 RSUs from a January 6, 2021 grant of 10,800 RSUs. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:55 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 42,500 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001415889-23-000691 · form4-01092023_090127.xml · derivative · entry 2 Hill Emily Luisa · CIK 0001778279 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2033-01-04 F2 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:55 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 19,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000691 · form4-01092023_090127.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,759 F1 · shares: Restricted stock units granted on January 5, 2023 that vest in four equal installments over four years, commencing on January 5, 2024. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 20:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 7,910 | $37.78 | $298,823.98 |
DisclosureSEC source: 0001415889-22-003564 · form4-04012022_010454.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,259 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2022. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $37.30 to $38.20 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:58 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 553 | $40.00 | $22,121.11 |
DisclosureSEC source: 0001179110-22-000837 · edgar.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,169 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,325 RSUs from a January 29, 2020 grant of 9,300 RSUs. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:01 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 211 | $39.31 | $8,295.25 |
DisclosureSEC source: 0001179110-22-000629 · edgar.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,722 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 909 RSUs from a January 22, 2019 grant of 3,636 RSUs. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:18 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 58,500 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001179110-22-000398 · edgar.xml · derivative · entry 3 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,500 Underlying: Common Stock · 58,500 shares Expires 2032-01-06 F3 · derivative.exercise_date: This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:18 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 15,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-000398 · edgar.xml · nonDerivative · entry 2 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,933 F2 · shares: Restricted stock units granted on January 7, 2022 that vest in four equal installments over four years, commencing on January 7, 2023. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:18 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 800 | $38.53 | $30,820.00 |
DisclosureSEC source: 0001179110-22-000398 · edgar.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,333 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,700 RSUs from a January 6, 2021 grant of 10,800 RSUs. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 173 | $41.16 | $7,121.03 |
DisclosureSEC source: 0001179110-22-000303 · edgar.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,133 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 600 RSUs from a January 3, 2018 grant of 2,400 RSUs Read SEC document |
| February 01, 2021 Filed Feb 2, 2021 23:24 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 541 | $56.96 | $30,813.20 |
DisclosureSEC source: 0001179110-21-001105 · edgar.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,306 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,325 RSUs from a January 29, 2020 grant of 9,300 RSUs. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 21:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 275 | $62.05 | $17,064.85 |
DisclosureSEC source: 0001179110-21-000874 · edgar.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,847 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 909 RSUs from a January 22, 2019 grant of 3,636 RSUs. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 9,278 | $33.02 Strike: $33.02 | $306,359.56 |
DisclosureSEC source: 0001179110-21-000538 · edgar.xml · derivative · entry 12 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,932 Underlying: Common Stock · 9,278 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to written a Rule 10b5-1 plan adopted by the Reporting Person on May 20, 2020. F4 · derivative.exercise_date: This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 10,500 | $18.01 Strike: $18.01 | $189,105.00 |
DisclosureSEC source: 0001179110-21-000538 · edgar.xml · derivative · entry 11 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Underlying: Common Stock · 10,500 shares Expires 2028-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to written a Rule 10b5-1 plan adopted by the Reporting Person on May 20, 2020. F3 · derivative.exercise_date: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 3,825 | $11.23 Strike: $11.23 | $42,954.75 |
DisclosureSEC source: 0001179110-21-000538 · edgar.xml · derivative · entry 10 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,825 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to written a Rule 10b5-1 plan adopted by the Reporting Person on May 20, 2020. F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 2,430 | $30.86 Strike: $30.86 | $74,989.80 |
DisclosureSEC source: 0001179110-21-000538 · edgar.xml · derivative · entry 9 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,430 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to written a Rule 10b5-1 plan adopted by the Reporting Person on May 20, 2020. F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 9,278 | $69.75 | $647,140.50 |
DisclosureSEC source: 0001179110-21-000538 · edgar.xml · nonDerivative · entry 8 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,122 F1 · kind: The transactions reported in this Form 4 were effected pursuant to written a Rule 10b5-1 plan adopted by the Reporting Person on May 20, 2020. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 9,278 | $33.02 | $306,359.56 |
DisclosureSEC source: 0001179110-21-000538 · edgar.xml · nonDerivative · entry 7 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to written a Rule 10b5-1 plan adopted by the Reporting Person on May 20, 2020. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 10,500 | $69.75 | $732,375.00 |
DisclosureSEC source: 0001179110-21-000538 · edgar.xml · nonDerivative · entry 6 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,122 F1 · kind: The transactions reported in this Form 4 were effected pursuant to written a Rule 10b5-1 plan adopted by the Reporting Person on May 20, 2020. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 10,500 | $18.01 | $189,105.00 |
DisclosureSEC source: 0001179110-21-000538 · edgar.xml · nonDerivative · entry 5 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to written a Rule 10b5-1 plan adopted by the Reporting Person on May 20, 2020. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,825 | $69.75 | $266,793.75 |
DisclosureSEC source: 0001179110-21-000538 · edgar.xml · nonDerivative · entry 4 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,122 F1 · kind: The transactions reported in this Form 4 were effected pursuant to written a Rule 10b5-1 plan adopted by the Reporting Person on May 20, 2020. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 3,825 | $11.23 | $42,954.75 |
DisclosureSEC source: 0001179110-21-000538 · edgar.xml · nonDerivative · entry 3 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to written a Rule 10b5-1 plan adopted by the Reporting Person on May 20, 2020. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,430 | $69.75 | $169,492.50 |
DisclosureSEC source: 0001179110-21-000538 · edgar.xml · nonDerivative · entry 2 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,122 F1 · kind: The transactions reported in this Form 4 were effected pursuant to written a Rule 10b5-1 plan adopted by the Reporting Person on May 20, 2020. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:15 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,430 | $30.86 | $74,989.80 |
DisclosureSEC source: 0001179110-21-000538 · edgar.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to written a Rule 10b5-1 plan adopted by the Reporting Person on May 20, 2020. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:18 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 63,000 | $0.00 Strike: $66.49 | $0.00 |
DisclosureSEC source: 0001179110-21-000474 · edgar.xml · derivative · entry 2 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires 2031-01-05 F2 · derivative.exercise_date: This option was granted on January 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:18 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 10,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-000474 · edgar.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,122 F1 · shares: Restricted stock units granted on January 6, 2021 that vest in four equal installments over four years, commencing on January 6, 2022. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 22:02 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 176 | $62.37 | $10,977.12 |
DisclosureSEC source: 0001179110-21-000415 · edgar.xml · nonDerivative · entry 2 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,322 F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 600 RSUs from a January 3, 2018 grant of 2,400 RSUs Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 22:02 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 112 | $62.37 | $6,985.44 |
DisclosureSEC source: 0001179110-21-000415 · edgar.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,498 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 383 RSUs from a January 3, 2017 grant of 1,530 RSUs. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 20:06 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,581 | $52.50 | $135,502.50 |
DisclosureSEC source: 0001070081-20-000112 · wf-form4_159363395083819.xml · nonDerivative · entry 1 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,610 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 28, 2020. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:43 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 64,250 | $0.00 Strike: $51.16 | $0.00 |
DisclosureSEC source: 0001070081-20-000052 · wf-form4_158050700018201.xml · derivative · entry 2 Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,250 Underlying: Common Stock · 64,250 shares Expires 2030-01-28 F2 · derivative.exercise_date: This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.